Gastric Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against gastric cancer and guarantee the finest results for our customers all over the world.

Gastric Cancer

Gastric cancer, also known as stomach cancer, is a cancer that develops from the lining of the stomach. Gastric cancer is the fifth leading cause of cancer in the world, the third leading cause of death from cancer. The most common cause is Helicobacter pylori infection, accounting for more than 60% of all cases. Other risk factors include smoking, dietary factors such as pickles vegetables and obesity. Early symptoms may include nausea, loss of appetite, heartburn and upper abdominal pain. Later signs and symptoms may include vomiting, weight loss, difficulty swallowing, yellowing of the skin and whites of the eyes as well as hematochezia. Cancer may spread from the stomach to other parts of the body, especially the lungs, abdomen, liver, lymph nodes and bones.

Therapeutic Vaccines for Gastric Cancer

Vaccines stimulate the immune system to generate a humoral or cellular response. Protein-bound polysaccharide K (PSK), derived from the CM-101 strain of the fungus Coriolus versicolor, is used as a tumor vaccine in GC. It was administered to patients after gastrectomy for stage II/III GC. 254 patients received adjuvant oral fluoropyrimidine chemotherapy or immunochemotherapy (chemotherapy + PSK). Though the 5-year survival rates were equivalent in both arms, the patients with LN disease had an improved 5-year OS of 47.8% with immunochemotherapy compared to 22.8% with chemotherapy.

In a more recent phase II multicenter study, patients with metastatic or unresectable GC or GEC received G17DT (nine-amino acid epitope derived from gastrin-17) with chemotherapy (cisplatin/5-FU). 69% of the patients who developed an immune response (responders) had a longer time to progression, with median OS of 10.03 months compared to 3.8 months for nonresponders. In another phase I/II trial, 22 patients with advanced GC, HLA-A24-restricted vascular endothelial growth factor receptor (VEGFR)-1, and VEGFR-2 vaccines were administered with S1 and cisplatin chemotherapy. The partial response rate was 55%, with median time to progression of 9.6 months and median OS of 14.2 months. Better response rates were documented in patients who showed increased cytotoxic T lymphocytes in response to the vaccine.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the gastric cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.